Eli Lilly, a prominent global healthcare corporation dedicated to patient well-being and research advancement, has declared a substantial investment of 750 million euros over the next two years for the production of cutting-edge pharmaceuticals at the Sesto Fiorentino hub in Tuscany—a site recognized for its innovation and strategic importance in Italy’s biotech drug production landscape.
This latest commitment elevates Eli Lilly’s cumulative investments in Italy to 1.4 billion euros over the last two decades.
Since 1959, Eli Lilly has been manufacturing medications near Florence, reaching more than 60 countries globally, with 95% of its products being exported and offering therapeutic solutions to over 7 million patients each year.
The newly announced investment aims to expand drug manufacturing specifically for diabetes and obesity treatment. Moreover, Eli Lilly has established partnerships with leading Italian entities to further diversify its product portfolio in Italy, with a focus on oncology drugs and Alzheimer’s treatment.
Projections indicate that this investment will contribute 1.5 billion euros to the Italian GDP and generate over 6,000 jobs nationwide. The event unveiling this initiative, aptly named “This is the future,” underscores a positive outlook on Italy’s role in the pharmaceutical sector. Distinguished figures from local and national institutions, including the mayor of Florence, the president of the Tuscany Region, the vice president of the Senate, and ministers responsible for Enterprises, Made in Italy, and Health, graced the occasion.
